A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
- Registry ID
- EUCTR2007-005302-44
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- GlaxoSmithKline Research & Development Limited
- Start date
- 2008-02-07
- Completion date
- 2008-05-21
- Last update
- 2026-08-16
Conditions
- Seasonal allergic rhinitis
Summary
To investigate effect of repeat intranasal doses of azelastine hydrochloride alone vs. GSK256066 + azelastine hydrochloride on nasal symptoms of allergic rhinitis provoked by spending 4h in the Vienna Challenge Chamber.
Locations
View on source registry